Oct. 24 at 4:37 PM
MAIN POST:
Big Pharma's M&A wave isn't slowing—it's accelerating into 2026.
$MRK $JNJ $SNY desperately plugging patent cliff revenue holes. But here's the smarter play:
$GS collects fees on every deal.
Trading at
$781 (15.5x earnings, below
$SPY average) and
$44 off September highs, Goldman is positioned perfectly.
Lower rates, desperate acquirers, and frozen IPOs lead to more deals, resulting in more GS fees.
Don't gamble on which biotech gets bought—follow the money to Wall Street's M&A king.
Goldman Sachs Long-Term Price Chart (1997-2025) - Shows a steady upward trajectory with a September 2025 record high at
$825, currently trading at
$781.
The chart demonstrates GS's consistent performance across multiple market cycles, validating the bullish technical setup with clear upside potential to new highs.
